In the nucleus, Lapatinib treatment led to the downregulation of the cell proliferation and cancer prognosis maker (KI-67), G2/mitotic-specific cyclin-B1 (CCNB1), and cell cycle G1/S and G2/M transition as a whole as represented by a highly interconnected network of nuclear proteins (AURKA, AURKB, CDK1, CDCA5, CCNB1, TOP2A, SFN, TPX2, KIF2C, KIFC1, KIF22, KIF23, NUSAP1, PRC1, ECT2, RACGAP1, FANCM, ANLN, UHRF1). Here, ECT2 is linked to cancer.